ENSAYOS CLÍNICOS DE MELANOMA, TUMORES CUTÁNEOS, PULMÓN, SARCOMAS Y CABEZA - CUELLO

MELANOMA

GEM-1802

“MULTICENTRE PHASE II CLINICAL TRIAL TO EVALUATE THE ACTIVITY OF ENCORAFENIB AND BINIMETINIB BEFORE LOCAL TREATMENT IN PATIENTS WITH BRAF MUTATED MELANOMA WITH METASTASIS TO THE BRAIN.”

https://clinicaltrials.gov/ct2/show/NCT03898908?term=GEM-1802&draw=2&rank=1

CA045-001

“A Phase 3, Randomized, Open-label Study of NKTR-214 Combined with Nivolumab Versus Nivolumab in Participants with Previously Untreated Unresectable or Metastatic Melanoma”

https://clinicaltrials.gov/ct2/show/NCT03635983?term=CA045-001&rank=1

MK7902-003

“A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) and Lenvatinib (E7080/MK-7902) Versus Pembrolizumab Alone as First-line Intervention in Participants with Advanced Melanoma (LEAP-003)”

https://clinicaltrials.gov/ct2/show/NCT03820986?term=MK7902-003&rank=1

MO39136

“A PHASE II TWO COHORT STUDY EVALUATING THE SAFETY AND EFFICACY OF COBIMETINIB PLUS ATEZOLIZUMAB IN BRAFV600 WILD-TYPE MELANOMA WITH CENTRAL NERVOUS SYSTEM METASTASES AND COBIMETINIB PLUS ATEZOLIZUMAB AND VEMURAFENIB IN BRAFV600 MUTATION-POSITIVE MELANOMA WITH CENTRAL NERVOUS SYSTEM METASTASES”

https://clinicaltrials.gov/ct2/show/NCT03625141?term=MO39136&rank=1

REGENERON (R2810-ONC-1788)

“A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA”

INCMGA 0012-201

“A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma”
https://clinicaltrials.gov/ct2/show/NCT03599713?term=INCMGA+0012-201&rank=1

GO40558

“A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF RO7198457 IN COMBINATION WITH PEMBROLIZUMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED MELANOMA”

MERKLIN 2

“Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1”

CABEZA Y CUELLO

INDUCE-3

“A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma”

INTERLINK-1

“Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer (INTERLINK-1)”
https://clinicaltrials.gov/ct2/show/NCT04590963?term=INTERLINK+1&draw=2&rank=1

J2G-MC-JZJB

“A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer”
**PULMÓN**

**MK-7902-00**


https://clinicaltrials.gov/ct2/show/NCT03829319?term=MK+7902+006&draw=2&rank=1

**TAK300X3-A300X3/BRIGATINIB 3001**

“An Efficacy Study Comparing Brigatinib Versus Alectinib in Advanced Anaplastic Lymphoma Kinase-Positive (ALK+) Non-Small-Cell Lung Cancer (NSCLC) Participants Who Have Progressed on Crizotinib (ALTA-3)”

https://clinicaltrials.gov/ct2/show/NCT03596866?term=BRIGATINIB+3001&draw=2&rank=1

**BO29554 (8-FAST)**

“A PHASE II/III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE TARGETED THERAPIES AS TREATMENTS FOR PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING ACTIONABLE SOMATIC MUTATIONS DETECTED IN BLOOD (BFAST: BLOOD FIRST ASSAY SCREENING TRIAL)

https://clinicaltrials.gov/ct2/show/NCT03178552?term=BO29554&rank=1

**LUNAR (EF-24)**

“Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapies for treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure”

https://clinicaltrials.gov/ct2/show/NCT02973789?term=LUNAR+%28EF-24%29&rank=1

**MK3475-671**

“A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/-Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (NSCLC) (KEYNOTE-671)”

https://clinicaltrials.gov/ct2/show/NCT03425643?term=MK3475-671&rank=1
CACZ885T2301

“A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)”

https://clinicaltrials.gov/ct2/show/NCT03447769?term=CACZ885T2301&rank=1

MM-398-01 (RESILIENT)

“Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer”


CA209-73L

“A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)”


TAK 788-3001

“A Randomized Phase 3 Multicenter Open-label Study to Compare the Efficacy of TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy in Patients With Non–Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutation”


GO41854

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB AND TIRAGOLUMAB COMPARED WITH DURVALUMAB IN PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER WHO HAVE NOT PROGRESSED AFTER CONCURRENT PLATINUM-BASED CHEMORADIATION


BLU 667-2303

A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non- Small Cell Lung Cancer

CINC280A2301

A phase III, randomized, controlled, open-label, multicenter, global study of capmatinib versus SoC docetaxel chemotherapy in previously treated patients with EGFR wt, ALK negative, locally advanced or metastatic (stage IIIB/IIIC or IV) NSCLC harboring MET exon 14 skipping mutation


MARIPOSA

1ª LINEA.

A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

https://clinicaltrials.gov/ct2/show/NCT04487080?term=MARIPOSA&draw=2&rank=1

SARCOMAS

GEIS 40

“Phase II, single arm, non-randomized and multicenter clinical trial of regorafenib as a single agent in the first-line setting for patients with metastatic and/or unresectable KIT/PDGFR Wild Type GIST”

https://clinicaltrials.gov/ct2/show/NCT02638766?term=REGISTRI&rank=1

GEIS 42

“Three versus five years of adjuvant imatinib as treatment of patients with operable GIST with a high risk for recurrence: A randomised phase III study”

https://clinicaltrials.gov/ct2/show/NCT02413736?term=SSGXXII&rank=1

GEIS 51

“Ensayo fase II multicéntrico de palbociclib en segunda línea de sarcomas avanzados con sobreexpresión CDK4”

https://clinicaltrials.gov/ct2/show/NCT03242382?term=GEIS+51&rank=1